肿瘤突变负荷可预测晚期NSCLC免疫检查点抑制剂相关不良事件
这项单中心队列研究纳入1215例接受免疫检查点抑制剂(ICI)±化疗的晚期NSCLC患者,基线TMB经OncoPanel NGS评估。34.7%发生irAE,较高TMB与irAE风险增加(aOR=1.04,p<0.001)及更早发生(aHR=1.02,p=0.002)相关。TMB≥90百分位(19 mut/Mb)预测最强(aOR=2.14,p<0.001;aHR=1.58,p=0.004),且该组肿瘤CD8+细胞富集(p=0.04)。
要点
- 高TMB与irAE风险增加及更早发生独立相关。
- TMB≥19 mut/Mb是irAE风险与早发的最强预测阈值。
- 高TMB肿瘤CD8+细胞富集,提示生物学机制。
核心结论
- 高TMB,尤其TMB≥19 mut/Mb,与irAE风险增加和更早发生相关,独立于免疫治疗暴露时间。
- 该关联可能由CD8+细胞富集的肿瘤生物学驱动,支持TMB作为irAE生物标志物。
研究设计与样本
- 单中心队列研究,纳入1215例接受ICI±化疗且OncoPanel NGS评估TMB的晚期NSCLC患者。
- 63.4%接受ICI单药,61.4%一线治疗;采用逻辑回归和Cox比例风险模型分析TMB与irAE关联。
- 采用多重免疫荧光评估肿瘤组织免疫细胞密度(CD8+、PD-1+、CD8+PD-1+、FOXP3+)。
主要发现
- 421例(34.7%)发生irAE。
- 较高基线TMB与irAE风险增加相关(aOR=1.04,p<0.001),与更早发生irAE相关(aHR=1.02,p=0.002)。
- TMB≥90百分位(19 mut/Mb)对比低于该阈值:irAE风险aOR=2.14(p<0.001),更早发生aHR=1.58(p=0.004)。
- 6、9、12周 landmark 分析中,调整年龄、性别、ECOG PS、PD-L1和治疗类型后,TMB≥90百分位与更高irAE风险相关。
- TMB≥90百分位肿瘤较低于该阈值者富集CD8+细胞(p=0.04)。
关键数值与推荐
- TMB≥90百分位定义为19 mut/Mb。
- 高TMB与irAE风险增加独立相关(aOR=1.04,p<0.001)。
- TMB≥19 mut/Mb预测irAE风险aOR=2.14(p<0.001),早发aHR=1.58(p=0.004)。
临床怎么用
- 对接受ICI±化疗的晚期NSCLC患者,基线TMB≥19 mut/Mb提示irAE风险增高且可能更早出现。
- 高TMB患者应加强irAE监测与早期识别,尤其在前12周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICIs) with or without chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs). METHODS: This monocentric cohort study included patients with advanced NSCLC receiving ICIs with or without chemotherapy who had available TMB assessed by OncoPanel next-generation sequencing. Baseline TMB was correlated with irAEs using both logistic regression and Cox proportional hazards models. Multiplex immunofluorescence was used to assess immune cells density (CD8+, PD-1+, CD8+PD-1+, FOXP3+) in tumor tissue according to TMB. RESULTS: Among 1215 patients with advanced NSCLC receiving ICIs with or without chemotherapy, 63.4% were treated with ICI alone and 61.4% were treated in the first line. A total of 421 patients (34.7%) developed irAEs. Higher baseline TMB was associated with an increased risk of developing irAE (adjusted odds ratio = 1.04, p < 0.001) and earlier irAE onset (adjusted hazard ratio = 1.02, p = 0.002). Baseline TMB more than or equal to the 90th percentile (19 mut/Mb) was the strongest predictor of both increased irAE risk (adjusted odds ratio = 2.14, p < 0.001) and earlier irAE onset (adjusted hazard ratio = 1.58, p = 0.004), compared with TMB less than the 90th percentile. Using 6-, 9-, and 12-week landmark analyses, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, PD-L1, and treatment type, TMB more than or equal to the 90th percentile was associated with a higher risk of irAE at 6, 9, and 12 weeks. Tumors with TMB more than or equal to the 90th percentile were enriched with CD8+ cells (p = 0.04) compared with tumors with TMB less than the 90th percentile. CONCLUSION: These findings indicate that a high TMB, particularly TMB more than or equal to the 19 mut/Mb, is associated with an increased risk and earlier irAE onset, independent of longer immunotherapy exposure. This association seems to be biologically driven by tumors enriched in CD8+ cells, supporting the role of elevated TMB as an irAEs biomarker.
引用
- Pecci F, Wang X, Santo V, et al. Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report. J Thorac Oncol. 2026. PMID: 42556463. doi:10.1016/j.jtho.2026.104136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。